01—Abstract
Summary
Summary of the 8-K filed November 5, 2025. Cited figures are marked; the original filing is the authoritative source.
IQVIA Holdings Inc. filed this Current Report on Form 8-K dated November 5, 2025, to disclose the Board of Directors' appointment of William G.
Kaelin Jr., M.D. to the Board on that date. The Board determined that Dr. Kaelin satisfies the New York Stock Exchange definition of "independent director." He will participate in the non-employee director compensation arrangements described in the company's proxy statement dated February 28, 2025, and is expected to enter into the company's standard indemnification agreement with non-management directors. The company also issued a press release announcing the appointment, furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure).
That press release describes Dr. Kaelin as a Senior Physician-Scientist at Brigham and Women's Hospital, Sidney Farber Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, and an Investigator at the Howard Hughes Medical Institute. It notes that he shared the 2019 Nobel Prize in Physiology or Medicine and that he serves on the board of Eli Lilly and Company, where he chairs the Science and Technology Committee. Chairman and CEO Ari Bousbib is quoted welcoming him to the board.
The filing contains no financial results, guidance, or transaction disclosures. Its investor relevance is limited to board refreshment and the addition of an independent director with scientific and oncology expertise.
02—Key points
Key Highlights
- William G. Kaelin Jr., M.D. was appointed to IQVIA's Board of Directors effective November 5, 2025.
- The Board determined that Dr. Kaelin satisfies the NYSE definition of "independent director."
- Dr. Kaelin will participate in the company's non-employee director compensation arrangements, as described in the February 28, 2025 proxy statement.
- He is expected to enter into the company's standard indemnification agreement with non-management directors.
- Dr. Kaelin is a 2019 Nobel Prize laureate in Physiology or Medicine for work on oxygen sensing and the von Hippel-Lindau tumor suppressor protein.
- He currently serves on the board of Eli Lilly and Company, where he chairs the Science and Technology Committee.
- The appointment was announced by press release (Exhibit 99.1) furnished under Item 7.01 (Regulation FD Disclosure).
03—Questions
Frequently Asked Questions
Who was appointed to IQVIA's Board of Directors?
William G. Kaelin Jr., M.D. was appointed to the Board effective November 5, 2025. He is a Senior Physician-Scientist at Brigham and Women's Hospital and a professor at Dana-Farber Cancer Institute and Harvard Medical School.
Is the new director considered independent?
Yes. The Board determined that Dr. Kaelin satisfies the New York Stock Exchange definition of "independent director."
How will the new director be compensated?
Dr. Kaelin will participate in the company's non-employee director compensation arrangements, as described under "Director Compensation" in the proxy statement dated February 28, 2025, for the 2025 annual meeting of stockholders.
Will the director receive indemnification protection?
Dr. Kaelin is expected to enter into the company's standard indemnification agreement with non-management directors, a form filed as Exhibit 10.8 to the Form 8-K filed October 3, 2016, and incorporated by reference.
What expertise does Dr. Kaelin bring to the board?
According to the press release, he has deep expertise in oncology and biomedical innovation. He has received the Albert Lasker Basic Medical Research Award, among other honors, and is the author of hundreds of peer-reviewed publications.
04—Continue